Piper Sandler has appointed three new co-heads in its healthcare investment banking, consumer investment banking and equity capital markets (ECM) groups to support continued growth and deepen client relationships. In healthcare, Brandon Rice and Chad Huber join veteran co-head Peter Day, bringing expertise in disruptive medical technology M&A and life sciences equity transactions respectively. In consumer, Carlos Sanchez joins Damon Chandik and Janica Lane as co-heads of consumer M&A advisory, reflecting a surge in deal flow across food & beverage, direct-to-consumer and retail segments. In ECM, Paul Scansaroli pairs with David Stadinski to lead global equity origination and execution, leveraging Scansaroli’s track record in financing growth-stage healthcare companies and institutional investors. Firm leaders cite these promotions as critical to scaling Piper Sandler’s platform and accelerating the next phase of revenue expansion in sectors that delivered year-over-year fee growth of over 15%.

Piper Sandler’s advisory and corporate finance segments are benefiting from a resurgence in biotech funding and mid-market private equity activity. Equity capital markets volumes have risen by approximately 20% year-to-date, supported by elevated equity valuations in life sciences. Debt capital markets remain healthy as issuers lock in coupons near multi-year lows. The firm’s forward P/E multiple of 22x positions it below peers such as Evercore at 26x, while trading slightly above Lazard’s sub-20x valuation, suggesting room for multiple expansion given Piper Sandler’s stronger revenue growth trajectory. Management reports robust deal pipelines in both M&A advisory—where completed transactions climbed by 30% last quarter—and equity financings, underscoring the firm’s ability to capture fee pools in a recovering biotech landscape.